BSECompany Update5d ago · 14 Nov 2026, 07:05 pm

statement of deviation and variation of funds for q ended 30th sept 2026

Sandu Pharmaceuticals Ltd · 524703

✦ AI SummaryResults

Sandu Pharmaceuticals Ltd has filed a statement of deviation and variation of funds for the quarter ended 30th September 2026, related to the preferential issue of equity shares (private placement) raised on 28th February 2022. The company has utilized the proceeds for the revamping of the capital, developing marketing infrastructure, and purchasing new/ additional plant and machinery.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Sandu Pharmaceuticals Ltd - 524703 - Statement Of Deviation And Variation Of Funds For Q Ended 30Th September 2026

Attachments (1)

📄

80f231fd-6b77-4f0a-8eb0-7e62e2678db6.pdf

pdf

Download →
View document text
ou SANDU PHARMACEUTICALS LIMITED (CIN:L24233GA1985PLC001587 SAMDU w Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in Ref: Corp. Sec/BSE/2026-27/509 Dated:14/11/2026 Department of Corporate Services Bombay Stock Exchange Limited, Phirojshah Jeejobhoy tower, Dalal Street, Mumbai-400001. the Q ended 30.09.2026 Pursuant to the provisions of Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular no CIR/CFD/CMD1/162/2019 Dated December 24, 2019 regarding “Format on Statement of Deviation or Variation for proceeds of Public issue, right issue, preferential issue, Qualified Institutions Placement (QIP) etc Please find enclosed herewith a statement of deviation or variation, duly reviewed by the Audit Committee of the Company and approved by Board , is given in “Annexure -A” for the 01 and 02"%and 03"Tranche. You are requested to kindly take note of the same. Thanking you, Yours Faithfully, For Sandu Pharmaceuticals Limited Pratika Mhambray Company Secretary & Compliance Officer AN ISO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai — 400 071 Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in u SANDU PHARMACEUTICALS LIMITED CIN:L24233GA1985PLC001587 Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in Name of Listed Sandu Pharmaceuticals Limited Entity Mode of Fund | Preferential issue of Equity Shares (Private Placement) Raising Date of Raising | 31-03-2021(25% upfront amount of the Share Warrants) Funds Amount Raised 2,63,79,653 Report filed for | 30" September 2026 Quarter ended Monitoring Agency Monitoring _ Agency name if applicable Is there a NO Deviation/Variation in use of funds raised If yes, whether the Not Applicable same is pursuant to change in terms contract or objects, which was approved by the shareholders If yes, date of | NotApplicable Shareholders Approval Explanation for the Not Applicable Deviation/Variation Audit Committee after review of the statement has noted and approved the same Comments of the Audit Committee after review Comments of the No Comments Auditors, if any Objects for which funds have been raised and where there has been a deviation, in the foll g table Original object Modified Original Modified | Funds Utilised | Amountof | Remarks Objects, if | Allocation | Allocation, Deviation/Vari | ifany any if any ation for the quarter accordintgo applicable object The Company shall Not Rs NA Rs NIL NIL use the proceeds | applicable | 2,63,79,653 2,63,79,653 from the proposed issue towards the revamping of the i capital developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery AN ISO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai — 400 071 Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in S -ti/ SANDU PHARMACEUTICALS LIMITED A CIN:L24233GA1985PLC001587 m Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 24074/7 4 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company AN ISO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai — 400 071. Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in u SANDU PHARMACEUTICALS LIMITED CIN:L24233GA1985PLC001587 Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in Name of Listed Sandu Pharma ceuticals Limited Entity Preferential issue of Equity Shares (Private Placement) Mode of Fund Rai Date of Raising 28-02- 2022 (75% allotment monies against the allotment of8,89,667 equity shares on Funds the conversion of 8,89,667 Warrants at the price of Rs. 20.69 per warrant) Amount Raised Rs 1,38,05,408 Report filed for 30" Septembe r 2026 Quarter ended Monitoring Agency NA Monitoring _ Agency | NA name if applicable Is there a | NO Deviation/Variation in use of funds raised If yes, whether the Not Applicable same is pursuant to change in terms contract or objects, which was approved by the shareholders If yes, date of Not Applicable Shareholders Approval Explanation for the Not Applicable Deviation/Variation Audit Committee after review of the statement has noted and approved the same Comments of the Audit Committee after review Comments of the No Comments Auditors, if any Objects for which funds have been raised and where there has been a deviation, in the following table Original object Modified Original Modified Amount of | Remarks Objects, if Allocation Allocati Deviation | if any any on, if /Variation any for the quarter according The Company shall Not Rs 1,38,05,408 NA Rs 1,38,05,408 NIL use the proceeds | applicable from the proposed issue towards the revamping of the i capital developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional AN ISO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai — 400 071 Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in S -fl;-/ SANDU PHARMACEUTICALS LIMITED A CIN:L24233GA1985PLC001587 m Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 24074/7 4 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in plant and machinery of the company, working capital requirement, investment in technologies and for general purpose which shall enhance the business of the Company AN ISO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai — 400 071. Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in S Ru7 SANDU PHARMACEUTICALS LIMITED A CIN:L24233GA1985PLC001587 w Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in Name of Listed Sandu Pharmaceuticals Limited Entity Mode of Fund | Preferential issue of Equity Shares (Private Placement) Raising Date of Raising | 14% July 2022 Funds Amount Raised Rs 1,31,94,934 Report filed for | 30" September 2026 Quarter ended Monitoring Agency | NA Monitoring Agency | NA name if applicable Is there a | NO Deviation/Variatio n in use of funds raised If yes, whether the | Not Applicable same is pursuant to change in terms contract or objects, which was approved by the shareholders If yes, date of | Not Applicable Shareholders Approval Explanation for the | Not Applicable Deviation/Variatio Comments of the | Audit Committee after review of the statement has noted and approved the same Audit Committee after review Comments of the | No Comments Auditors, if any Objects for which funds have been raised and where there has been a deviation, in the following table Modified Modifie | Funds Utilized Amount of Remark Objects, if | Allocation d Deviation/Varia | sifany any Allocati tion for the on, if quarter any according to applicable object The Company shall | Not Rs 1,31,94,934 NA | Rs 66,45,748.19 NIL NIL use the proceeds | applicable from the proposed issue towards the revamping of the capital developing marketing infrastructure, civil work, required for major plant and machinery, AN ISO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, [Showing first 8,000 characters — download PDF for full document]